Aqualung is an early stage biotech company developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung, and systemic inflammation. Incorporated in 2016 and led by a physician scientist, Aqualung's science-driven approach led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic inflammatory diseases. The pipeline of ALT is designed to help in a range of diseases characterized by unchecked local and systemic inflammation: Acute Respiratory Distress Syndrome (ARDS), Ventilator- and Radiation-Induced Lung Injuries, Prostate Cancer, Pulmonary Hypertension, Pulmonary Fibrosis and Chorioamnionitis. These conditions have a significant unmet medical need and many exhibit significant morbidity and mortality.